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CD40 Ligand Inhibits Endothelial Cell Migration by Increasing
Production of Endothelial Reactive Oxygen Species
Carmen Urbich, PhD; Elisabeth Dernbach; Alexandra Aicher, MD;
Andreas M. Zeiher, MD; Stefanie Dimmeler, PhD
Background—The CD40/CD40 ligand system is involved in atherogenesis. Activated T lymphocytes and platelets, which
express high amounts of CD40 ligand (CD40L) on their surface, contribute significantly to plaque instability with
ensuing thrombus formation, leading to acute coronary syndromes. Because reendothelialization may play a pivotal role
for plaque stabilization, we investigated a potential role of CD40L on endothelial cell (EC) migration.
Methods and Results—Stimulation of ECs with recombinant CD40L prevented vascular endothelial growth factor
(VEGF)-induced EC migration, as determined by a “scratched wound assay.” In addition, activated T lymphocytes and
platelets significantly inhibited VEGF-induced EC migration and tube formation in vitro. Because the activation of
endothelial nitric oxide (NO) synthase and the release of NO are required for EC migration and angiogenesis, we
analyzed the effect of NO. Coincubation with the NO donor S-nitroso-N-acetyl-penicillamine (SNAP) did not reverse
the inhibitory effect of CD40L on VEGF-induced EC migration and tube formation. In addition, EC migration induced
by SNAP was completely inhibited by CD40L. CD40L, however, induced the production of reactive oxygen species and
reduced endothelial NO bioavailability. This reactive oxygen species–dependent effect of CD40L stimulation was
reversed with vitamin C or N-acetylcysteine.
Conclusions—The activation of the CD40 receptor inhibits EC migration by increasing reactive oxygen species. The
blockade of EC migration by CD40L may critically affect endothelial regeneration after plaque erosion and thereby may
contribute to the increased risk for development of acute coronary events in patients with high circulating levels of
CD40L. (Circulation. 2002;106:981-986.)
Key Words: migration n ligands n endothelium n nitric oxide n reactive oxygen species
The CD40 receptor (CD40) and CD40 ligand (CD40L/CD154) were originally found to be expressed on B and T
lymphocytes and to be involved in T cell–dependent B-cell
differentiation and activation.1,2 However, recent data indicate
that the CD40/CD40L system plays an important role not only in
cellular immunity and inflammation but also in the pathophys-
iology of atherosclerosis.1 The CD40/CD40L system was shown
to be expressed in nonhematopoietic cells, including endothelial
cells (ECs), fibroblasts, and smooth muscle cells.3 Ligation of
CD40 on these cell types induces a proinflammatory and
prothrombotic response, as evidenced by the release of inflam-
matory cytokines, expression of adhesion molecules, activation
of matrix metalloproteinases (MMPs), and procoagulant tissue
factor (reviewed in Reference 2). Blockade of CD40L by
neutralizing antibodies or genetic disruption of the CD40 ligand
in mice prevents the initiation and progression of atherosclerosis
and induces a more stable plaque phenotype.4–7
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The clinical sequela of acute coronary syndromes (ACSs)
is a result of either plaque rupture or plaque erosion with
concomitant thrombus formation. Activated T lymphocytes
and platelets, which express high amounts of CD40L on their
surface, contribute significantly to plaque instability with
ensuing thrombus formation.2 In accordance with this, pa-
tients with ACSs exhibit enhanced blood levels of soluble and
membrane-bound CD40L.8 Moreover, high levels of soluble
CD40L were associated with increased cardiovascular events
in women,9 suggesting that CD40 activation may be involved
in the development of ACS.
Endothelial injury and denudation of the endothelial mono-
layer caused by spontaneous plaque erosion or coronary
angioplasty contribute to acute thrombotic events and further
progression of the atherosclerotic lesion. The role of CD40/
CD40L on reendothelialization is not known. Therefore, we
investigated the effect of CD40L on EC migration using an in
vitro “scratched wound assay.” Recombinant CD40L com-
pletely blocked vascular endothelial growth factor (VEGF)-
induced EC migration. EC migration was also inhibited by
activated platelets or T cells, the biological sources of
CD40L. We further elucidated the underlying signaling
pathways and demonstrate that CD40L stimulated the pro-
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duction of reactive oxygen species (ROSs) by ECs, which
antagonizes endothelial nitric oxide (NO) production. Be-
cause EC migration also contributes to angiogenesis, we
investigated the effect of CD40L in a human angiogenesis
assay and demonstrated a potent inhibition by CD40L.
Methods
Cell Culture
Pooled human umbilical vein ECs (HUVECs) were purchased from
Cell Systems/Clonetics and cultured until the third passage as
previously described.10 CD40 ligand was kindly donated by Immu-
nex (Seattle, Wash) or purchased from Alexis. VEGF was purchased
from Calbiochem, S-nitroso-N-acetyl-penicillamine (SNAP) from
Alexis, vitamin C from Sigma), N-acetylcysteine (NAC) from
Sigma, and anti-CD40L antibody from Calbiochem. HUVECs were
exposed to laminar fluid flow (15 dynes/cm2) in a cone-and-plate
apparatus as previously described.10
Scratched Wound Assay
In vitro scratched wounds were created by scraping the cell mono-
layer with a sterile disposable cell scraper.11 After injury of the
monolayer, the cells were gently washed and stimulated. EC migra-
tion from the edge of the injured monolayer was quantified by
measurement of the distance between the wound edges before and
after injury with a computer-assisted microscope (Zeiss) at 5 distinct
positions (every 5 mm).
Platelet Preparation and Activation
Platelets were obtained from healthy human subjects as previously
described.10 After resuspension, 1.53108 platelets were incubated
with HUVECs and were activated with 0.2 U/mL human thrombin
(Boehringer Mannheim). Cell culture dishes were centrifuged at
700g for 2 minutes, and thrombin was neutralized after 5 minutes
with 2 U/mL hirudin (Boehringer Mannheim).
T Cell Isolation and Activation
Human mononuclear cells were obtained from the blood of healthy
human volunteers by density gradient centrifugation using Biocoll
separating solution (density 1.077; Biochrom). CD31-positive T cells
were purified from mononuclear cells by positive selection with
anti-CD3 microbeads (Miltenyi Biotec) with a magnetic cell sorter
device (Miltenyi Biotec). Purity assessed by fluorescence-activated
cell sorter (FACS) analysis was .95%.
DAF-2 DA and H2DCFDA Staining
Cells were stained with the membrane-permeable 4,5-diaminofluo-
rescein diacetate (DAF-2 DA, 10 mmol/L, Calbiochem) or dichloro-
dihydrofluorescein diacetate (H2DCFDA; 10 mmol/L; Molecular
Probes). The amount of NO or ROSs generated was determined by
computer-assisted fluorescence densitometric analysis.11,12 For
FACS analysis, cells were incubated with DAF-2 DA (10 mmol/L, 3
hours) or DCFDA (10 mmol/L, 30 minutes), washed, and detached
with trypsin.13 After centrifugation, NO or ROS generation was
immediately determined by FACS analysis using a FACScan flow
cytometer (BD Biosciences) and Cell Quest software (BD
Biosciences).
Angiogenesis Assays
The human angiogenesis assay was performed according to the
instructions of the manufacturer (Cell Systems/Clonetics). Briefly,
human ECs were cocultured with human fibroblasts in a culture
matrix and stimulated over a period of 11 days. Cells were fixed and
stained with an anti-CD31 antibody and a secondary antibody
conjugated with alkaline phosphatase and BCIP/NBT as substrate.
Angiogenesis was quantified by measuring tube length with a
computer-assisted microscope.
In addition, the formation of tube-like structures was determined
with a matrigel assay. HUVECs (13105 cells/mL) were seeded in
endothelial basal medium supplemented with growth factors and
10% FCS on Matrigel basement membrane matrix (BD Biosciences).
To investigate the effect of CD40L on VEGF-induced tube forma-
tion, HUVECs were cultured in endothelial basal medium supple-
mented with growth factors and 5% FCS on growth factor-reduced
Matrigel (BD Biosciences). The length of tube-like structures was
measured by light microscopy after 48 hours in a blinded fashion.
Statistical Analysis
Data are expressed as mean6SEM from $3 independent experi-
ments. Statistical analysis was performed by t test. ANOVA was
performed for serial analyses.
Results
Recombinant CD40L Inhibits EC Migration
To investigate the effect of CD40L on EC migration,
HUVECs were incubated with VEGF (50 ng/mL) in the
presence or absence of CD40L, and migration was assessed
by a scratched wound assay.11 Incubation of HUVECs with
human recombinant CD40L dose-dependently inhibited
VEGF-induced cell migration (Figure 1A). The inhibitory
effect of CD40L was not caused by an increase in EC death,
because 0.1 to 5 mg/mL CD40L did not induce EC apoptosis
(5 mg/mL CD40L: 11266% annexin-positive cells compared
with control, n54). Moreover, EC proliferation was not
affected by CD40L addition (control: 0.1960.07 versus
CD40L: 0.1860.08 bromodeoxyuridine incorporation [opti-
cal density], n53). To test whether CD40L generally inter-
feres with EC migration, we used shear stress as an additional
important physiological stimulus for EC migration.14 Inter-
estingly, CD40L did not affect shear stress–induced EC
migration (shear stress: 184614% of control versus shear
stress1CD40L: 17765% of control, n54). Likewise, basic
fibroblast growth factor (bFGF)-stimulated cell migration
was not inhibited by CD40L (bFGF: 158615% of control
versus bFGF1CD40L: 159614% of control, n54).
Activated T Cells and Platelets Inhibited
VEGF-Induced EC Migration
Activated platelets and T cells are the major physiological
source for release of CD40L under pathophysiological con-
ditions.15,16 Therefore, T cells or platelets were used as a
stimulus for CD40 activation in ECs. Platelets were added to
the ECs and were activated by thrombin treatment for 5
minutes, which is known to trigger CD40L release. As shown
in Figure 1B, VEGF-induced EC migration was significantly
abrogated by the addition of activated platelets, whereas
unstimulated platelets did not show any effect. Importantly,
the inhibition of VEGF-induced EC migration by activated
platelets was reversed by neutralizing antibodies directed
against CD40L. Control experiments demonstrated that
thrombin or hirudin, used to inactivate thrombin, had no effect
on EC migration in the absence of platelets (Figure 1B).
Similar results were obtained when phorbol 12-myristate
13-acetate (PMA)–activated CD31-positive T cells were used,
which express CD40L on the cell surface. Again, activated T
cells significantly inhibited VEGF-induced EC migration (Fig-
ure 1C). The inhibitory effect induced by activated T cells was
partially dependent on CD40L (Figure 1C).
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In contrast, addition of unstimulated T cells resulted in a
minor reduction of EC migration, which was not affected by
neutralizing CD40L antibodies (Figure 1C). Thus, CD40
stimulation, induced by either human recombinant CD40L or
activated platelets and T cells, inhibits VEGF-induced EC
migration.
CD40L Reduces NO and Increases Oxidative Stress
Endothelial NO is critical for VEGF-induced EC migration and
angiogenesis.11,17 Therefore, we investigated the effect of
CD40L on endothelial NO production by using the fluorescence
dye DAF-2 DA.11 CD40L reduced basal endothelial NO to an
extent similar to that with the NOS inhibitor NG-monomethyl-
L-arginine, as assessed by immunofluorescence and FACS
analysis (Figure 2, A and B). Furthermore, CD40L prevented
VEGF-stimulated increase of NO (data not shown).
NO bioavailability can be reduced by ROS, which can
react with NO.18 Because CD40L increases ROS formation in
B cells,19 we determined ROS formation in ECs in response
to CD40L. CD40L time-dependently increased formation of
endogenous ROS with maximum levels after 6 hours, as
determined by immunofluorescence and FACS analysis using
H2DCFDA (Figure 2, C and D, and data not shown). The
levels of ROSs detected after CD40L stimulation are about
half of that measured after addition of 500 mmol/L exogenous
H2O2 for 15 minutes (Figure 2, C and D). The antioxidant
vitamin C prevented both the increase in ROSs and the
decrease in NO levels, suggesting that the formation of ROSs
is causally involved in the reduction of NO (Figure 2).
Next, we tested the functional involvement of CD40L-
mediated disturbance of NO and ROSs balance for VEGF-
induced EC migration. Therefore, HUVECs were incubated
with the exogenous NO-donor SNAP (20 mmol/L), which is
known to stimulate EC migration.20 As shown in Figure 3A,
CD40L significantly inhibited SNAP-induced cell migration.
In addition, SNAP did not reverse the inhibitory effect of
CD40L on EC migration (Figure 3A). In contrast, the
antioxidants vitamin C and NAC reversed the inhibitory
effect of CD40L on VEGF-induced EC migration (Figure
3B). Moreover, H2O2 directly prevented EC migration (Figure
3B). These data suggest that CD40L prevents VEGF-induced
EC migration by increasing oxidative stress.
Antioxidants Reverse the Inhibitory Effect of CD40
Stimulation on VEGF-Induced Tube Formation
To finally investigate whether the inhibitory effect of CD40L
on VEGF-induced EC migration also affects angiogenesis, a
human angiogenesis assay was used.20 Cells were incubated
with human recombinant VEGF (10 ng/mL) in the presence
or absence of human recombinant CD40L (0.5 mg/mL). As
shown in Figure 4, A and B, CD40L inhibited basal and
VEGF-induced tube formation. Similar effects were detected
when angiogenesis was measured in a Matrigel assay (Figure
4, C and D). The inhibition of VEGF-stimulated tube forma-
tion was reversed by coincubation of the antioxidants vitamin
C or NAC (Figure 4, A and B). In contrast, the NO donor
SNAP did not prevent CD40L-induced inhibition of tube
formation (Figure 4, A and B).
Discussion
The data of the present study demonstrate that activation of
the CD40 receptor by human recombinant CD40L inhibits
basal and VEGF-induced EC migration, leading to a reduc-
tion of reendothelialization in vitro. The inhibitory effect was
also achieved when activated platelets or T lymphocytes,
which are well-established sources for CD40L,15,16 were
Figure 1. Recombinant CD40L, activated platelets, and CD31-
positive T cells inhibit VEGF-induced EC migration. A,
HUVECs were incubated with VEGF (50 ng/mL) and recombi-
nant CD40L for 24 hours, and cell migration was detected by
use of a scratched wound assay. Data are mean6SEM; n54;
*P,0.05 vs VEGF. B, HUVECs were scraped and incubated
with VEGF (50 ng/mL) and anti-CD40L antibody (10 mg/mL).
Then 1.53108 platelets were added to HUVECs and activated
with 0.2 U/mL human thrombin (Boehringer Mannheim). Cell
culture dishes were centrifuged at 700g for 2 minutes, and
thrombin was neutralized after 5 minutes with 2 U/mL hirudin
(Boehringer Mannheim). Cell migration was detected after 24
hours. Data are mean6SEM; n55; *P,0.05 vs VEGF;
#P,0.05 vs VEGF1activated platelets. C, CD31-positive T
cells were activated for 5 hours at 37°C with PMA (5 ng/mL)
and washed twice with PBS to remove PMA. Activated T
cells were incubated as indicated with anti-CD40L antibody
(10 mg/mL) for 30 minutes and added to scratched HUVECs.
Cell migration was detected after 24 hours. Data are
mean6SEM; n55; *P,0.05 vs VEGF.
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coincubated with ECs. Thus, CD40L released from activated
platelets or T lymphocytes at sites of plaque erosion might
impair reendothelialization, thereby further aggravating
thrombotic events. Indeed, previous clinical studies demon-
strated that patients with unstable angina had significantly
higher levels of circulating soluble CD40L.8 Moreover, ele-
vated concentrations of CD40L in apparently healthy women
are associated with a significantly increased risk of future
cardiovascular events.9 Particularly in women, ACSs are
more likely to be secondary to plaque erosion.21 EC migration
is essential to reendothelialize denuded plaque areas to
prevent thrombus formation. Therefore, one may speculate
that endothelial regeneration might be disturbed by high
levels of CD40L, which may contribute to increased risk for
the development of acute coronary events. Interestingly,
CD40L did not affect EC migration stimulated by laminar
flow. Endothelial injury occurs predominantly in plaque
surface areas with low or turbulent blood flow.22 Therefore,
laminar flow may prevent the inhibitory effect of CD40L on
reendothelialization and thereby protect these areas from
extensive plaque erosion.10 Thus, CD40L may particularly
affect the ECs within regions prone to plaque erosion.
Our data further revealed that CD40L blocks VEGF-
induced angiogenesis. These data are in contrast to previous
studies, which demonstrate that CD40L stimulates MMP and
VEGF expression and promotes vascularization.23–25 The
reason for these discrepancies is unclear. To rule out a
potential influence by the CD40L used, we tested recombi-
nant CD40L provided by 2 different sources. Moreover,
activated T cells and platelets were also shown to prevent
VEGF-induced EC migration in a manner that was at least
partially prevented by neutralizing CD40 antibodies. In ad-
dition, the experimental set-up was varied to test whether the
time point of incubation might have affected the inhibitory
potential of CD40L. However, CD40L potently blocked
VEGF-induced EC migration when added 1 hour before or
after VEGF stimulation (data not shown). Previous studies
demonstrated that CD40L increased MMPs, which contribute
to the stimulation of cell migration and improvement of
angiogenesis.23,26 Interestingly, under our experimental con-
ditions (medium with 10% FCS), CD40L did not stimulate
MMP3 release. In contrast, a potent 6-fold increase in MMP3
release was detected when cells were serum-depleted before
Figure 2. CD40L reduces NO and
increases oxidative stress. A and B,
HUVECs were incubated with recombi-
nant CD40L (0.5 mg/mL), vitamin C (VitC;
100 mmol/L), or NG-monomethyl-L-
arginine (LNMA; 1 mmol/L) for 6 hours.
A, Cells were stained with DAF-2 DA (10
mmol/L) for 3 hours. Amount of NO was
determined by FACS analysis. Top, Rep-
resentative histogram. Data are
mean6SEM; n54 (bottom). BG indicates
background. B, Cells were stained with
DAF-2 DA (10 mmol/L) for 5 minutes.
Amount of NO was determined by
computer-assisted fluorescence densito-
metric analysis. Top, Representative pic-
tures. Data are mean6SEM; n53;
*P,0.05 vs CD40L (bottom). C and D,
HUVECs were incubated with recombi-
nant CD40L (0.5 mg/mL) and vitamin C
(100 mmol/L) for 6 hours. H2O2 (500
mmol/L; 15 minutes) was used as a posi-
tive control. C, Cells were stained with
redox-sensitive dye H2DCFDA (10
mmol/L) for 30 minutes. Amount of ROSs
was determined by FACS analysis. Top,
Representative histogram. Data are
mean6SEM; n53 (bottom). D, Cells were
stained with H2DCFDA (10 mmol/L) for 5
minutes. Amount of ROSs was deter-
mined by computer-assisted fluores-
cence densitometric analysis. Top, Rep-
resentative pictures. Data are
mean6SEM; n53; *P,0.05 vs CD40L
(bottom).
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and during CD40L stimulation (data not shown). This exper-
imental set-up was used in the studies, which demonstrated a
proangiogenic effect of CD40L.23 Therefore, one may spec-
ulate about a context-dependent action of CD40L. Interest-
ingly, similar controversial findings are reported for other
cytokines, such as tumor necrosis factor-a, which elicits
proangiogenic and antiangiogenic responses.27
The mechanism by which CD40L inhibits VEGF-induced
EC migration and angiogenesis appears to involve the gen-
eration of ROSs. Stimulation of the CD40 receptor increased
intracellular formation of ROS with concomitant reduction of
NO. The antimigratory and antiangiogenic effects of CD40L
were reversed by antioxidants, suggesting that CD40L-
induced increase in ROSs mediates the inhibitory effects of
CD40L. In contrast, exogenous NO donors did not prevent
CD40L-mediated inhibition. Therefore, one may speculate
that the generation of ROSs is sufficient to inactivate NO and
thereby prevents NO-dependent EC migration. This is con-
sistent with previous findings that endothelial NO is essential
for both VEGF-induced cell migration and angiogenesis.11,17
Furthermore, stimulation of CD40 has previously been shown
to induce the generation of ROSs in B lymphocytes.19
Likewise, ROSs are mediators for other related receptors
Figure 4. CD40L inhibits VEGF-induced tube formation. A and B,
A human angiogenesis assay was used to measure tube formation.
Cells were stimulated with VEGF (10 ng/mL) with or without CD40L
(0.5 mg/mL) in presence or absence of SNAP (20 mmol/L), NAC
(200 mmol/L), or vitamin C (Vit C; 100 mmol/L). A, Representative
pictures. B, Angiogenesis was quantified by measuring tube length
with a computer-assisted microscope. Data are mean6SEM; n53;
*P,0.05 vs VEGF. C, HUVECs were incubated with or without
CD40L (0.5 mg/mL) on matrigel basement membrane matrix, and
length of tube-like structures was measured in a blinded fashion by
light microscopy after 48 hours. Data are mean6SEM; n53;
*P,0.05 vs control. D, HUVECs were incubated with VEGF (50
ng/mL) in presence or absence of CD40L (0.5 mg/mL) on growth
factor-reduced matrigel, and length of tube-like structures was
measured by light microscopy after 48 hours in a blinded fashion.
Data are mean6SEM; n53; *P,0.05 vs VEGF.
Figure 3. Antioxidants reverse the inhibitory effect of CD40
stimulation. A, HUVECs were incubated with VEGF (50 ng/mL),
SNAP (20 mmol/L), or CD40L (0.5 mg/mL). Cell migration was
detected after 24 hours with a scratched wound assay. Data are
mean6SEM; n54; *P,0.05 vs VEGF; #P,0.05 vs SNAP. B,
HUVECs were incubated with VEGF (50 ng/mL), CD40L (0.5
mg/mL), vitamin C (Vit C; 100 mmol/L), NAC (200 mmol/L), or
H2O2 (200 mmol/L) for 24 hours. Data are mean6SEM; n53;
*P,0.05 vs VEGF1CD40L.
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belonging to the tumor necrosis factor receptor family.28,29
Therefore, the CD40 receptor might activate similar intracel-
lular pathways.
ROSs play a critical role in vascular biology. Whereas
initially ROSs were expected to exert mainly toxic and
proapoptotic effects, increasing evidence suggests that they
also act as important physiological signaling molecules.30 In
line with these conflicting reports, ROSs also exert a double-
edged role in angiogenesis signaling. Consistent with our
data, various studies reported that ROSs inhibit EC migration
and angiogenesis.31 However, ROSs may also be critical for
EC migration,32,33 angiogenesis,34 and cell proliferation.33
The magnitude and the extent of ROS formation may underlie
these discrepancies. Thus, a promigratory involvement of
ROSs on EC migration was detected within 1 to 5 hours after
wounding.32 In contrast, CD40L-stimulated ROS formation is
long lasting, starting after 5 hours of incubation.
In conclusion, the present study demonstrates that activa-
tion of CD40 inhibits both EC migration and angiogenesis.
The inhibitory effect of CD40L was not related to the
induction of apoptosis or the blockade of cell cycle progres-
sion. The blockade of EC migration by CD40L may critically
affect endothelial regeneration after injury induced by plaque
erosion and thereby contribute to the increased risk for
development of acute coronary events in patients with high
circulating levels of CD40L.
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